Published in Neurology on June 27, 2014
Pediatric gliomas as neurodevelopmental disorders. Glia (2015) 0.77
126 novel mutations in Italian patients with neurofibromatosis type 1. Mol Genet Genomic Med (2015) 0.75
CNS Tumors in Neurofibromatosis. J Clin Oncol (2017) 0.75
Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A (1971) 31.05
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell (1990) 5.24
Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science (2002) 5.08
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell (2009) 4.82
Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet (2000) 3.98
Mouse models of tumor development in neurofibromatosis type 1. Science (1999) 3.40
Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell (1992) 3.30
Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet (1996) 3.08
Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol (2014) 3.01
Mouse tumor model for neurofibromatosis type 1. Science (1999) 2.89
Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell (2008) 2.84
Clinical and genetic aspects of neurofibromatosis 1. Genet Med (2010) 2.77
Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol (2007) 2.75
Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol (2002) 2.65
Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr (1994) 2.63
Neurofibromatosis type 1. J Am Acad Dermatol (2009) 2.41
Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res (2003) 2.30
An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet (2006) 2.23
Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell (2009) 2.12
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol (2012) 1.95
Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development (2005) 1.85
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest (2012) 1.83
Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet (2007) 1.80
Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res (2007) 1.69
Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol (2006) 1.63
Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet (2003) 1.62
Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc Natl Acad Sci U S A (2004) 1.55
Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res (2008) 1.47
Variable expression of neurofibromatosis 1 in monozygotic twins. Am J Med Genet A (2011) 1.45
Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. Genes Dev (2010) 1.43
Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A (2003) 1.28
Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol (2012) 1.27
Innate neural stem cell heterogeneity determines the patterning of glioma formation in children. Cancer Cell (2012) 1.26
Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J Neurosci (2010) 1.25
Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res (2008) 1.24
Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr (1995) 1.20
Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro Oncol (2007) 1.20
A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. J Med Genet (2011) 1.19
Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics (2011) 1.17
BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol (2012) 1.14
Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation. Ann Neurol (2013) 1.14
The pathoetiology of neurofibromatosis 1. Am J Pathol (2011) 1.13
Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol (2012) 1.03
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr Blood Cancer (2011) 1.02
Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res (2012) 1.02
Optic nerve dysfunction in a mouse model of neurofibromatosis-1 optic glioma. J Neuropathol Exp Neurol (2009) 1.01
Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation. Cancer Res (2011) 0.98
Clustering of mutations in the 5' tertile of the NF1 gene in Slovakia patients with optic pathway glioma. Neoplasma (2013) 0.96
Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology (2013) 0.96
The plexiform neurofibroma microenvironment. Cancer Microenviron (2012) 0.95
The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology (2006) 0.95
PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors. Cancer Res (2012) 0.94
Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12. Neuro Oncol (2012) 0.93
Development of an international internet-based neurofibromatosis Type 1 patient registry. Contemp Clin Trials (2012) 0.89
Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs (2013) 0.88
NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma. Oncogene (2013) 0.87
Neurofibromatosis type 1: diagnosis and recent advances. Expert Opin Med Diagn (2010) 0.86
Dissecting the clinical phenotype associated with mosaic type-2 NF1 microdeletions. Neurogenetics (2012) 0.83
Achieving consensus for clinical trials: the REiNS International Collaboration. Neurology (2013) 0.82
Visual acuity of children treated with chemotherapy for optic pathway gliomas. Pediatr Blood Cancer (2013) 0.79
Cognition before and after chemotherapy alone in children with chiasmatic-hypothalamic tumors. J Neurooncol (2008) 0.78